Vera Therapeutics, Inc.宣布，其针对成人免疫球蛋白A肾病（IgA肾病）治疗的生物制剂Atacicept，已获得美国食品药品监督管理局（FDA）授予的生物制剂许可申请（BLA）优先审评资格。
此次优先审评将显著缩短FDA的审评周期，意味着该创新疗法有望更快惠及患者。IgA肾病作为一种进展性自身免疫性肾病，目前临床治疗选择有限，Atacicept的研发进展备受业界关注。
Vera Therapeutics, Inc.宣布，其针对成人免疫球蛋白A肾病（IgA肾病）治疗的生物制剂Atacicept，已获得美国食品药品监督管理局（FDA）授予的生物制剂许可申请（BLA）优先审评资格。
此次优先审评将显著缩短FDA的审评周期，意味着该创新疗法有望更快惠及患者。IgA肾病作为一种进展性自身免疫性肾病，目前临床治疗选择有限，Atacicept的研发进展备受业界关注。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.